Efficacy of Mobile Phone Short Message Service (SMS) Reminders on Malaria Treatment Adherence and Day 3 Post-Treatment Reviews (SMS-RES-MAL) in Kenya: A Study Protocol
|Ambrose O Talisuna1,2*, Dejan Zurovac1,2, Sophie Githinji1, Amos Oburu1, Josephine Malinga1, Andrew Nyandigisi3, Caroline OH Jones1,2 and Robert W Snow1,2|
|1Department of Public Health Research, KEMRI-Welcome Trust Research Program, Kenya|
|2Centre for Tropical Medicine, Nuffield Department of Clinical Medicine, University of Oxford, UK|
|3Malaria Control Unit, Ministry of Health, Nairobi, Kenya|
|Corresponding Author :||Ambrose O Talisuna
Department of Public Health Research
KEMRI-Welcome Trust Research Program, Kenya
Tel: +254 724 220 289
Email: [email protected]
|Received February 23, 2015; Accepted March 18, 2015; Published March 23, 2015|
|Citation: Talisuna AO, Zurovac D, Githinji S, Oburu A, Malinga J, et al. (2015) Efficacy of Mobile Phone Short Message Service (SMS) Reminders on Malaria Treatment Adherence and Day 3 Post-Treatment Reviews (SMS-RES-MAL) in Kenya: A Study Protocol . J Clin Trials 5:217. doi:10.4172/2167-0870.1000217|
|Copyright: © 2015 Talisuna AO, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.|
Background: Mobile phone short messaging services (SMS) have been investigated in health information reporting, provider performance, drug and diagnostic stock management and patient adherence to treatment for chronic diseases. However, their potential role in improving patients’ adherence to malaria treatment and day 3 post treatment reviews remains unclear.
Methods/Design: A “proof of concept” open label randomised controlled trial will be conducted at four sites in Western Kenya. Principal research questions are: 1) Can mobile phone SMS reminders improve patient adherence to malaria treatment? 2) Can mobile phone SMS reminders improve day 3 post treatment reviews? Eligible caregivers (n=1000 per arm) of children under five years old with uncomplicated malaria will be randomly assigned (one to one) to: a) the current standard of care (provider counselling and health education); and b) the current standard of care plus SMS reminders. Within each arm, caregivers will be further randomized to three different categories. In categories 1 and 300 caregivers per arm per category will be visited at home on day 1 and 2 of follow up respectively, to measure appropriate timing and adherence of the second Artemether-Lumefantrine (AL) dose and doses 3 and 4. Further, caregivers in categories 1 and 2 will be required to come to the health facility for the day 3 post treatment reviews. Finally, in category 400 caregivers per arm will be visited at home on day 3 to measure adherence for the full AL course. Each category will be visited at home only once to avoid biases in the measures of adherence as a result of home consultations. Primary outcomes will be adherence to the full AL course (category 3), as well as, the proportion of patients reporting back for day 3 post treatment reviews (categories 1 and 2). The primary analysis will be intention-to-treat. Costs of the intervention will be measured over the period of the intervention, and a cost-effectiveness ratio will be estimated.
Discussion: If successful, evidence from this trial could improve malaria treatment adherence and offer pragmatic approaches for antimalarial drug resistance surveillance and risk mitigation in Africa.
Current Controlled Trials: ISRCTN39512726